A5064853433- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Venous Thromboembolism Diagnosis and Management
- Neuroblastoma Research and Treatments
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- CNS Lymphoma Diagnosis and Treatment
- Blood groups and transfusion
- Multiple and Secondary Primary Cancers
- Chronic Myeloid Leukemia Treatments
- Biochemical and Molecular Research
- Peripheral Neuropathies and Disorders
- Platelet Disorders and Treatments
- Cancer-related Molecular Pathways
- Cancer Genomics and Diagnostics
- DNA Repair Mechanisms
- Immunodeficiency and Autoimmune Disorders
- Central Venous Catheters and Hemodialysis
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
2017-2024
Ministry of Health of the Russian Federation
2017-2024
Research Center of Neurology
2013
The aim of our study is to evaluate the prognostic value morphological types ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) in children. We performed a retrospective analysis data on 81 cases pediatric ALK+ ALCL which had been diagnosed 2011–2022. All patients and/or their legal representatives signed voluntary informed consent for participation study, as well biological material testing. medical records was carried out accordance with internal rules Dmitry Rogachev National Medical...
The purpose of this work was evaluation prognostic significance 11q23/KMT2A rearrangements in infants (aged under 365 days) with B-cell precursor acute lymphoblastic leukemia (ALL) enrolled Russian-Belarus multicenter trial MLLBaby. This study is supported by the Independent Ethics Committee and approved Academic Council Research Institute Medical Cell Technologies (Ekaterinburg). Various were revealed 100 (72%) 139 patients. Event-free survival (EFS) intermediate risk group MLL-Baby 35.1%...
Burkitt lymphoma (BL) is one of the most common types non-Hodgkin in children. The application modern risk-adapted treatment regimens has resulted 85–90 % survival rates affected patients; however, prognosis still remains poor case relapsed/refractory disease. In standard protocols, patients were stratified into risk groups based primarily on disease stage and extent lactate dehydrogenase levels. Mutations TP53 gene are associated with a many tumors, lately there have been reports that...
Aim. To evaluate the safety and efficacy of crizotinib used in pediatric patients with relapsed or refractory ALK-positive anaplastic large-cell lymphoma (ALCL). Subjects methods. The paper describes experience 8 ALK-ALCL before after allogeneic hematopoietic stem cell transplantation (HSCT). Results. All (100%) treated were recorded to have complete responses, including metabolic ones (tumor disappearance as evidenced by positron emission tomography (PET)/computed tomography. Conclusion....
The relapse of acute lymphoblastic leukemia (ALL) in children is still a difficult task. This due both to the difficulties achieving a second remission and problems organizing allogeneic bone marrow transplantation (BMT) those patients who need it. standard approach use second-line drugs regime high-dosage chemotherapy blocks, but response rate for this treatment with early relapses remains low response time short. Recently, new drugs with different mechanisms action have appeared that...
The reduction of long-term survival and fertility is still a problem in management Hodgkin lymphoma children adolescents. These problems are partly solved by radiotherapy changing procarbazine on etoposide dacarbazine. We analyzed medical data patients with HL < 18 years that were treated modified OEPA-COPDAC protocol since 1.01.2012 to 01.12.2017. study was approved the Independent Ethics Committee Dmitry Rogachev National Medical Research Center Pediatric Hematology, Oncology,...
Today, treatment results for acute lymphoblastic leukemia (ALL) look encouraging, yet 10–15% patients still end up relapsing. The success of relapse is directly dependent on whether or not a tumor clone has been completely eradicated before hematopoietic stem cell transplantation (HSCT). Immunotherapy made it possible to achieve minimal residual disease (MRD) – negative remission even in refractory patients. One example such immunotherapeutic agents inotuzumab ozogamicin (InO), an anti-CD22...
Evans syndrome, a combination of autoimmune hemolytic anemia and immune thrombocytopenia, is rare disease in children. In childhood, it may turn out to be one the first manifestations primary immunodeficiency or an dysregulation syndrome. Here we present clinical case patient who was initially diagnosed with syndrome did not respond well therapy. Based on results genetic testing, child then immunodeficiency, namely, activated PI(3)kd During follow-up, developed lymphoma had undergo radical...
Nijmegen breakage syndrome (NBS) and ataxia-telangiectasia (AT; Louis–Bar syndrome) are primary immunodeficiencies (PID) associated with chromosome instability DNA repair defects that predispose individuals to an increased risk of various malignancies. In our study, we retrospectively analyzed clinical characteristics outcomes 28 cancer cases in 14 patients AT 10 NBS who had been treated at the Dmitry Rogachev National Medical Research Center Pediatric Hematology, Oncology Immunology between...
Despite remarksble improvements in the treatment of pediatric acute limphoblastic leukemia (ALL) over last decades, relapse still caries a poor prognosis with considerable morbidity and mortality. New strategies approaches are extremely needed. According to results previous protocol ALL-REZ-2014 despite implementation bortezomib, as well idarubicin navelbine, which have not been used first-line therapy, new had demonstrated no significant improvement reaching steady remission, especially for...
The effectiveness of treatment for children with B-cell non-Hodgkin lymphomas (B-NHL) has reached 85–90% after the introduction modern risk-adapted regimens that involve risk group stratification based on tumor stage. Bone marrow involvement is traditionally evaluated using quantitative morphological analysis cells which has, however, a lower sensitivity compared to molecular genetic methods. In our study, we used next generation sequencing (NGS) identify tumor-specific...
Acute lymphoblastic leukemia (ALL) is the most common oncological disease of childhood. With modern approaches to therapy, approximately 85% patients with ALL can be considered recovered. However, treatment relapses and resistant forms of the remains a problem. Carrying out high-dosage chemotherapy subsequent allogeneic TSCS the standard therapy for such patients. But this not always effective and, as rule, associated severe concomitant complications. The use immunotherapy – blinatumomab,...
Cancer increases the risk of venous thromboembolism (VTE) in adults and children. The aim our study was to evaluate incidence VTE children adolescents with lymphomas. approved by Independent Ethics Committee Dmitry Rogachev National Medical Research Center Pediatric Hematology, Oncology Immunology. A retrospective analysis based on medical data 262 (0–18 years) primary lymphomas (n = 262) who were treated Immunology since 01.01.2013 31.12.2019 had been performed. Such parameters as age sex...